Eplontersen is a Ligand-conjugated Antisense Oligonucleotide for Polyneuropathy of Hereditary Transthyretin Amyloidosis Research
On December 22, 2023, the U.S. Food and Drug Administration approved Eplontersen. And it is indicated for the study of transthyretin amyloid cardiomyopathy (ATTR-CM). Morever ATTR-CM is a systemic, progressive,…